P. Zarrinkar

发表

Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer.

D. Lockhart, J. Welsh, L. Sapinoso, 2001, Proceedings of the National Academy of Sciences of the United States of America.

A quantitative analysis of kinase inhibitor selectivity

Mindy I. Davis, L. Wodicka, P. Zarrinkar, 2008, Nature Biotechnology.

Comprehensive analysis of kinase inhibitor selectivity

Mindy I. Davis, L. Wodicka, P. Zarrinkar, 2011, Nature Biotechnology.

A small molecule–kinase interaction map for clinical kinase inhibitors

L. Wodicka, D. Lockhart, P. Zarrinkar, 2005, Nature Biotechnology.

Kinetic intermediates trapped by native interactions in RNA folding.

P. Zarrinkar, D. K. Treiber, J. Williamson, 1998, Science.

Kinetic intermediates in RNA folding.

P. Zarrinkar, J. Williamson, Williamson, 1994, Science.

The kinetic folding pathway of the Tetrahymena ribozyme reveals possible similarities between RNA and protein folding

P. Zarrinkar, J. Williamson, 1996, Nature Structural Biology.

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

P. Zarrinkar, Mazen W. Karaman, G. Pallares, 2009, Blood.

High-throughput kinase profiling as a platform for drug discovery

P. Zarrinkar, N. Gray, D. Goldstein, 2008, Nature Reviews Drug Discovery.

Arrays of arrays for high-throughput gene expression profiling.

D J Lockhart, D. Lockhart, D. Stern, 2001, Genome research.

Unique fatty acid composition of normal cartilage: discovery of high levels of n‐9 eicosatrienoic acid and low levels of n‐6 polyunsaturated fatty acids

P. Zarrinkar, W. Christie, R. Wuthier, 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Tuning a three-component reaction for trapping kinase substrate complexes.

Dustin J Maly, D. Lockhart, P. Zarrinkar, 2008, Journal of the American Chemical Society.

Response to Molecule–kinase interaction map

D. Lockhart, P. Zarrinkar, D. K. Treiber, 2005, Nature Biotechnology.

Arrays of arrays for high-throughput gene expression profiling.

D. Lockhart, D. Stern, J. Welsh, 2001, Genome research.

Human Pharmacokinetics of AC220, a Potent and Selective Class III Receptor Tyrosine Kinase Inhibitor.

P. Zarrinkar, J. Cortes, F. Giles, 2007 .

Reply to BIRB-796 is not an effective ABL(T315I) inhibitor

D. Lockhart, P. Zarrinkar, D. K. Treiber, 2005, Nature Biotechnology.

Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.

P. Zarrinkar, H. Patel, T. Carter, 2009, Journal of medicinal chemistry.

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

P. Zarrinkar, K. Yu, D. Brehmer, 2018, Cell.

Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.

Daniel K. Treiber, John Kuriyan, David J. Lockhart, 2006, Cancer research.

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

Andrew Kasarskis, Eric E. Schadt, John Kuriyan, 2012, Nature.

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.

William Pao, Harold Varmus, Daniel K Treiber, 2005, Proceedings of the National Academy of Sciences of the United States of America.

High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors.

Randall W King, Xianming Deng, Stefan Knapp, 2011, Chemistry & biology.

KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition

P. Zarrinkar, Patricia Greninger, C. Benes, 2018, Clinical Cancer Research.

Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.

Daniel K Treiber, Mindy I. Davis, L. Wodicka, 2010, Chemistry & biology.

Elucidation of the kinetic folding pathway of a Group I intron

P. Zarrinkar, 1996 .

An Internally Controlled Quantitative Target Occupancy Assay for Covalent Inhibitors

Yi Liu, P. Zarrinkar, M. R. Janes, 2018, Scientific Reports.

The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors

Yi Liu, Jun Feng, Pingda Ren, 2018, Nature Structural & Molecular Biology.

An Internally Controlled Quantitative Target Occupancy Assay for Covalent Inhibitors

P. Zarrinkar, Yi Liu, M. R. Janes, 2018, Scientific Reports.

The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors

P. Zarrinkar, U. Peters, Yi Liu, 2018, Nature Structural & Molecular Biology.

Clinical Pharmacokinetics and FLT3 Phosphorylation of AC220, a Highly Potent and Selective Inhibitor of FLT3

P. Zarrinkar, Darren E. Insko, M. Levis, 2008 .

Discovery and optimization of a highly efficacious class of 5-aryl-2-aminopyridines as FMS-like tyrosine kinase 3 (FLT3) inhibitors.

P. Zarrinkar, Darren E. Insko, R. Armstrong, 2015, Bioorganic & medicinal chemistry letters.

treatment of acute myeloid leukemia (AML) AC220 is a uniquely potent and selective inhibitor of FLT3 for the

P. Zarrinkar, Mazen W. Karaman, G. Pallares, 2013 .

Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicine

P. Zarrinkar, Zhou Zhu, P. Rejto, 2016, BMC Genomics.

The P9.1-P9.2 peripheral extension helps guide folding of the Tetrahymena ribozyme.

P. Zarrinkar, J. Williamson, 1996, Nucleic acids research.

Optimizing the substrate specificity of a group I intron ribozyme.

P. Zarrinkar, B. Sullenger, 1999, Biochemistry.

Slow folding kinetics of RNase P RNA.

P. Zarrinkar, J. Williamson, J R Williamson, 1996, RNA.

Phase 1 AML Study of AC220, a Potent and Selective Second Generation FLT3 Receptor Tyrosine Kinase Inhibitor

P. Zarrinkar, J. Cortes, M. Levis, 2008 .

P. Zarrinkar, H. Patel, T. Carter, 2009, Journal of medicinal chemistry.

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

A. Kasarskis, P. Zarrinkar, E. Schadt, 2012, Nature.

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

P. Zarrinkar, Mazen W. Karaman, H. Patel, 2009, Blood.